Stephen K. Brannan, MD

JCP
Antipsychotic Efficacy of KarXT (Xanomeline−Trospium)
Original Research

image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ May 11, 2022

This post hoc analysis of phase 2 data evaluated rates and time course of response with the new combination oral agent KarXT (xanomeline−trospium) in the treatment of schizophrenia.
Peter J. Weiden, Alan Breier, Sarah Kavanagh, et al
JCP
Original Research

June 15, 2005

Pedro L. Delgado, Stephen K. Brannan, Craig H. Mallinckrodt, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe